Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoPACT: Pembrolizumab + Chemo in TNBC
NCT03639948Phase 2Active, not recruiting
- Sponsor
- University of Kansas Medical Center
- Start
- Sep 2018
- Primary completion
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by University of Kansas Medical Center. Primary endpoint: Pathological Complete Response Rate at 25 weeks. Started Sep 2018; status: active, not recruiting.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03639948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03639948.